A carregar...
Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report
BACKGROUND: Catumaxomab, the first anti-EpCAM antibody, was approved in 2009 for the treatment of malignant ascites in cancer patients with EpCAM positive tumors. We consider this case of interest as treatment with catumaxomab not only prolonged the puncture-free interval but also showed a systemic...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3880167/ https://ncbi.nlm.nih.gov/pubmed/24380380 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-618 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|